Table 3.

Associations of plasma fibroblast growth factor 2 concentration with atherosclerosis progression

	Model 1		Model 2		Model 3
Variables	Odds Ratio	P Value	Odds Ratio	P Value	Odds Ratio	P Value
FGF-2, per 50 pg/ml	0.86 (0.76–0.96)	0.008	0.85 (0.75–0.95)	<0.01	0.86 (0.76–0.96)	0.02
Hosmer–Lemeshow P value	0.94		0.76		0.22
FGF-2 lowest tertile, 3–64 pg/ml	Reference		Reference		Reference
FGF-2 middle tertile, 65–119 pg/ml	0.61 (0.37–0.99)	0.05	0.65 (0.39–1.01)	0.11	0.70 (0.40–1.20)	0.20
FGF-2 highest tertile, 120–865 pg/ml	0.42 (0.26–0.68)	<0.001	0.43 (0.26–0.72)	0.001	0.48 (0.28–0.82)	<0.01
Hosmer–Lemeshow P value	1.00		0.19		0.69

First and second rows: model using levels of FGF-2 as a continuous variable. Third to sixth rows: model using levels of FGF-2 as tertiles. Model 1: unadjusted analysis; model 2: adjusted by age and sex; model 3: model 2 plus smoking status, diabetes, dyslipidemia, plaque presence at baseline, stage of CKD, intima-media thickness, body mass index, serum levels of glucose, total cholesterol, high-sensitivity C-reactive protein, 25-hydroxyvitamin D, and phosphate. All models included 431 patients (262 progressors and 169 nonprogressors). The lowest tertile of FGF-2 included 143 patients (102 progressors and 41 nonprogressors). The middle tertile of FGF-2 included 143 patients (86 progressors and 47 nonprogressors). The highest tertile of FGF-2 included 145 patients (74 progressors and 71 nonprogressors).